Advanced PAP, Supplemental Oxygen, and Complex Ventilatory Support Concepts

1. Treatment-Emergent Central Sleep Apnea and Complex Sleep Apnea

Treatment-emergent central sleep apnea (the older complex sleep apnea context) occurs when central apneas appear or become prominent after obstructive events are controlled with PAP — the airway is open, but the brain's drive to breathe becomes unstable (often from loop-gain and CO2 dynamics). The technologist recognizes it during PAP monitoring when central events emerge with absent effort and a patent airway. Recognition and documentation are technologist tasks; diagnosis and management belong to the physician.

2. Adaptive Servoventilation (ASV) and Contraindication Screening

Adaptive servoventilation (ASV) is a form of servo ventilation that continuously measures breathing and adjusts pressure support breath-by-breath to stabilize central and periodic breathing — servo control responding dynamically to the patient's own pattern. Because a large trial found harm in a specific population, ASV requires contraindication screening: it is generally contraindicated in symptomatic heart failure with reduced left-ventricular ejection fraction (LVEF) (for example, LVEF ≤ 45%). Screening for heart failure and LVEF is a mandatory, physician-level step before ASV use; the technologist supports it by ensuring the screening and order are documented.

3. Volume-Assured Pressure Support and Hypoventilation

When the problem is hypoventilation — not moving enough air, so CO2 rises — patency alone is not enough. Volume-assured pressure support modes (AVAPS, average volume-assured pressure support, and iVAPS, intelligent volume-assured pressure support) automatically adjust pressure support to deliver a target ventilation. They are used in neuromuscular disease (weak respiratory muscles), obesity hypoventilation syndrome (OHS), and COPD. CO2 monitoring (transcutaneous or end-tidal) and oxygen-saturation tracking assess whether ventilation is adequate. These modes are physician-prescribed and managed with respiratory-therapy collaboration.

How it works

1. The physician identifies a need beyond standard PAP — central events, hypoventilation, or persistent hypoxemia — and issues an order.
2. For ASV, contraindication screening (heart failure and LVEF) is completed and documented first.
3. The prescribed mode is applied: ASV varies pressure support to stabilize central/periodic breathing; volume-assured modes target a set ventilation.
4. The technologist monitors airflow, effort, SpO2, and — when indicated — CO2, documenting oxygenation and ventilation adequacy.
5. Supplemental oxygen is entrained per order if hypoxemia persists despite adequate PAP.
6. Findings are escalated to the physician and respiratory therapy, who adjust therapy; the technologist documents and supports, not prescribes.

Common confusions

Memory aids

"CASES need a VET." — Central events → ASV (screen LVEF/heart failure); Supplemental O2 for SpO2; Escalate; Volume-assured for Effort (hypoventilation) → Target ventilation. Simpler: "ASV = servo, AVAPS = volume, O2 = entrain."

Quick review

Topic Recap

Advanced therapy steps in where standard PAP stops: treatment-emergent central sleep apnea (central events emerging on PAP), hypoventilation syndromes, and persistent hypoxemia. ASV uses servo-driven, breath-by-breath pressure support to stabilize central and periodic breathing but requires mandatory contraindication screening for symptomatic heart failure with reduced LVEF. Volume-assured modes (AVAPS/iVAPS) target a set ventilation for neuromuscular disease, OHS, and COPD, guided by CO2 monitoring as well as SpO2. Supplemental oxygen is entrained per order to correct residual hypoxemia. Every advanced mode is governed by a prescriber order and protocol, delivered with respiratory-therapy collaboration, with the technologist recognizing, documenting, and escalating — never prescribing.

Knowledge Check

1. Which pattern suggests treatment-emergent central sleep apnea during PAP?
2. What is the key contraindication screening required before ASV use?
3. Which modes target a set ventilation volume for hypoventilation?
4. Why is CO2 monitoring used alongside oximetry during ventilatory support?
5. How is supplemental oxygen delivered with PAP when hypoxemia persists?

Answers and Rationales

1. Central apneas (absent airflow with absent effort) or periodic breathing that appears or worsens after obstruction is controlled. Emergence of central events on PAP defines the treatment-emergent pattern.
2. Symptomatic heart failure with reduced left-ventricular ejection fraction (LVEF). A landmark trial showed harm in this group, so ASV is generally contraindicated there.
3. Volume-assured pressure support modes such as AVAPS and iVAPS. They automatically adjust pressure support to deliver a target ventilation.
4. Because a normal SpO2 can hide hypoventilation; rising CO2 is the direct sign of inadequate ventilation. CO2 monitoring catches what oximetry can miss.
5. By entraining (bleeding) oxygen into the PAP circuit under a physician order, while continuing to monitor oxygen saturation. Oxygen is added to the airflow rather than replacing PAP pressure.